OMEICOS Therapeutics was founded in 2013 and is a biopharmaceutical company focused on developing first-in-class small molecule therapies for the prevention and treatment of cardiovascular diseases. Its research particularly targets conditions such as atrial fibrillation, aiming to address unmet medical needs through innovative drug development. By leveraging advanced scientific approaches, OMEICOS Therapeutics works to improve patient outcomes and expand treatment options in cardiovascular care.